Gene signatures for cancer research: A 25-year retrospective and future avenues
PLOS Computational Biology · 16.10.2024 · 20 (10) · e1012512
DOI: 10.1371/journal.pcbi.1012512 ↗Kurz gefasst
Historischer Beitrag in der Zeitschrift PLOS Computational Biology, online erschienen am 16.10.2024. Verfasst von Wei Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, China. Hauptthemen laut MEDLINE: Gene Expression Profiling, Neoplasms, Transcriptome. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union–Next Generation EU programme, European Union – Next Generation EU programme, Ministero della Ricerca of Italy.
Abstract (Originalsprache)
Over the past two decades, extensive studies, particularly in cancer analysis through large datasets like The Cancer Genome Atlas (TCGA), have aimed at improving patient therapies and precision medicine. However, limited overlap and inconsistencies among gene signatures across different cohorts pose challenges. The dynamic nature of the transcriptome, encompassing diverse RNA species and functional complexities at gene and isoform levels, introduces intricacies, and current gene signatures face reproducibility issues due to the unique transcriptomic landscape of each patient. In this context, discrepancies arising from diverse sequencing technologies, data analysis algorithms, and software tools further hinder consistency. While careful experimental design, analytical strategies, and standardized protocols could enhance reproducibility, future prospects lie in multiomics data integration, machine learning techniques, open science practices, and collaborative efforts. Standardized metrics, quality control measures, and advancements in single-cell RNA-seq will contribute to unbiased gene signature identification. In this perspective article, we outline some thoughts and insights addressing challenges, standardized practices, and advanced methodologies enhancing the reliability of gene signatures in disease transcriptomic research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, China.
- Dipartimento di Informatica Sistemistica e Comunicazione, Università di Milano-Bicocca, Milan, Italy.
- Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Davide Chicco
Förderung
- European Union–Next Generation EU programme
- European Union – Next Generation EU programme
- Ministero della Ricerca of Italy
Zitieren
APA
Liu, W., He, H., & Chicco, D. (2024). Gene signatures for cancer research: A 25-year retrospective and future avenues. PLOS Computational Biology, 20(10), e1012512. https://doi.org/10.1371/journal.pcbi.1012512
Vancouver
Liu W, He H, Chicco D. Gene signatures for cancer research: A 25-year retrospective and future avenues. PLOS Computational Biology. 2024;20(10):e1012512. doi:10.1371/journal.pcbi.1012512
BibTeX
@article{Liu2024,
author = {Liu, Wei and He, Huaqin and Chicco, Davide},
title = {Gene signatures for cancer research: A 25-year retrospective and future avenues},
journal = {PLOS Computational Biology},
year = {2024},
volume = {20},
number = {10},
pages = {e1012512},
doi = {10.1371/journal.pcbi.1012512}
}
EUVIMED